English
Dutch
French
Russian
Spanish
Cannabis investments are growing “like a weed.” With 2019 worldwide spending on Cannabis products potentially exceeded $24 billion, initially benchmarked by Statista[1], according to other industry research firms[2]. The total global spending on Cannabis is projected to increase to $63.5 billion by 2024, for a compound annual growth rate (CAGR) of 21%.
[1] Total CBD consumer sales U.S. 2014-2022 | Statista Research, Published by Matej Mikulic, Aug 9, 2019
[2]Industry Analysis of the Legal Marijuana Market 2018-2025 by Grandview Research, PublishedMay 2019
Hemp-Derived CBD and Industrial Products– “Hemp” is a term used to classify varieties of Cannabis that contain 0.3% or less THC content (by dry weight) and is legal in the US. The majority of the Fund’s portfolio focus is the creation of retail products and the capture of online, physical retail, and industrial channels. Hemp-derived CBD extracted from the Hemp plant is a cousin of the Cannabis plant. However, unlike the psychoactive properties of THC, CBD itself does not have the same legal restrictions as to its high THC Cannabis cousins. NAVF-Pharma will both private label big box – store brands and maintain its brands to gain market traction within the US and international markets, with attention to states where legislative entry is pending for High THC, medicinal products.
The Hemp Farming Act of 2018 was a proposed law to remove hemp (defined as Cannabis with less than 0.3% THC) from Schedule I controlled substances and making it an ordinary agricultural commodity. Its provisions were incorporated in the 2018 United States farm bill that became law on December 20, 2018.
International Operations Export / Import –Hemp-derived products may be imported and exported under the 2018 Farm Act.Several states such as Oregon, codified legal inter-state commerce of Medical Cannabis, potentially paving the way for free trade between states on Medical Cannabis, which would allow our cultivation and production facilities to run to full capacity. However, a greater focus is being placed on potential domiciles of operation such as Colombia and Thailand, which would allow cultivation and production of Medical Cannabis that our portfolio interests could provide to Canada, UK, and other European countries where it is legal to import.
Real Estate, Retail Development Supply, and Services: All distribution channels for medical Cannabis requires a physical presence. Our land acquisition and services portfolio interests will focus to acquire and develop legally compliant real estate locations for the purposes of leasing them to legal operators, which will utilize unified branding and produces, amongst other services provided within our portfolio interests. We will prefer that our operations are within a Qualified Opportunity Zone.
Canna-Pharma Drug R&D(Intellectual Property (“IP”), Creation & Acquisition): NAVF-Pharma R&D, will specialize in creating and acquiring IP of diversified products including pharmaceutical-Cannabis drug development, compounding, delivery systems, diagnostic equipment, and nutrition products. This IP would create a unique offering that would allow NAVF-Pharma’s “Canna-Pharma Drug R&D” Portfolio to provide new product offerings to the market that can be either sold to a 3rd party, licensed to the marketplace, distributed through NAVF’s own “Medical Cannabis License Acquisitions & Distribution” portfolio, or a combination thereof.This portfolio would operate as a research-based pharmaceutical manufacturer.
